Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

NCT06323369 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

154

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Tislelizumab（neoadjuvant）
DRUG: Cisplatin （neoadjuvant）
DRUG: Nab-paclitaxel （neoadjuvant）
PROCEDURE: Surgical resection
DRUG: Cisplatin（adjuvant）
DRUG: Tislelizumab（adjuvant）
RADIATION: Radiation
DRUG: Carboplatin（neoadjuvant）
DRUG: Carboplatin（adjuvant）

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University